Andrew Roberts

Therapeutic development and current uses of BCL-2 inhibition

Andrew W Roberts

Journal article  |  2020  |  Hematology

B-cell lymphoma 2 (BCL2) is a key protein regulator of apoptosis. It is variably highly expressed in many hematological malignanci..

Targeting MCL-1 in hematologic malignancies: Rationale and progress

Andrew H Wei, Andrew W Roberts, Andrew Spencer, Aaron Seth Rosenberg, David Siegel, Roland B Walter, Sean Caenepeel, Paul Hughes, Zach McIver, Khalid Mezzi, Phuong Khanh Morrow, Anthony Stein

Journal article  |  2020  |  Blood Reviews

Myeloid cell leukemia sequence 1 (MCL-1) is an antiapoptotic protein that plays a key role in promoting cell survival in multiple ..

Zanubrutinib for the treatment of patients with Waldenstrom macroglobulinemia: 3 years of follow-up

Judith Trotman, Stephen Opat, David Gottlieb, David Simpson, Paula Marlton, Gavin Cull, Javier Munoz, Alessandra Tedeschi, Andrew W Roberts, John F Seymour, Siminder Kaur Atwal, Yiling Yu, William Novotny, Eric Holmgren, Ziwen Tan, James D Hilger, Jane Huang, Constantine S Tam

Journal article  |  2020  |  Blood

Inhibitors of Bruton's tyrosine kinase (BTK) have established therapeutic activity in patients with Waldenström macroglobulinemia ..

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy

Chong Chyn Chua, Andrew W Roberts, John Reynolds, Chun Yew Fong, Stephen B Ting, Jessica M Salmon, Sarah MacRaild, Adam Ivey, Ing Soo Tiong, Shaun Fleming, Fiona C Brown, Sun Loo, Ian J Majewski, Stefan K Bohlander, Andrew H Wei

Journal article  |  2020  |  Journal of Clinical Oncology

PURPOSE: The B-cell lymphoma 2 (BCL-2) inhibitor venetoclax has an emerging role in acute myeloid leukemia (AML), with promising r..

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

Joanne E Davis, Sasanka M Handunnetti, Mandy Ludford-Menting, Chia Sharpe, Piers Blombery, Mary Ann Anderson, Andrew W Roberts, John F Seymour, Constantine S Tam, David S Ritchie, Rachel M Koldej

Journal article  |  2020  |  Blood Advances

Combination venetoclax plus ibrutinib for the treatment of mantle cell lymphoma (MCL) has demonstrated efficacy in the relapsed or..

Cotargeting BCL-2 and MCL-1 in high-risk B-ALL

Donia M Moujalled, Diane T Hanna, Soroor Hediyeh-zadeh, Giovanna Pomilio, Lauren Brown, Veronique Litalien, Ray Bartolo, Shaun Fleming, Maia Chanrion, Sebastien Banquet, Ana-Leticia Maragno, Laurence Kraus-Berthier, Marie Schoumacher, Charles G Mullighan, Angela Georgiou, Christine A White, Guillaume Lessene, David CS Huang, Andrew W Roberts, Olivier Geneste, et al.

Journal article  |  2020  |  BLOOD ADVANCES

Improving survival outcomes in adult B-cell acute lymphoblastic leukemia (B-ALL) remains a clinical challenge. Relapsed disease ha..

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Victor S Lin, Thomas E Lew, Sasanka M Handunnetti, Piers Blombery, Tamia Nguyen, David A Westerman, Bryone J Kuss, Constantine S Tam, Andrew W Roberts, John F Seymour, Mary Ann Anderson

Journal article  |  2020  |  Blood

Highly active BTK inhibitors (BTKis) and the BCL2 inhibitor venetoclax have transformed the therapeutic landscape for chronic lymp..

Undetectable minimal residual disease should be the goal of venetoclax therapy in relapsed and refractory chronic lymphocytic leukaemia

Thomas Lew, Mary Ann Anderson, Victor Lin, Sasanka Handunnetti, Neil Came, David Westerman, Wall Meaghan, Constantine Tam, Andrew W Roberts, John F Seymour

Conference Proceedings  |  2020  |  LEUKEMIA & LYMPHOMA

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

CD DiNardo, IS Tiong, A Quaglieri, S MacRaild, S Loghavi, FC Brown, R Thijssen, G Pomilio, A Ivey, JM Salmon, C Glytsou, SA Fleming, Q Zhang, H Ma, KP Patel, SM Kornblau, Z Xu, CC Chua, Xufeng Chen, P Blombery, et al.

Journal article  |  2020  |  Blood

The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for..

Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on

Piers Blombery, Ella R Thompson, Nguyen Tamia, Richard W Birkinshaw, Jia-Nan Gong, Xiangting Chen, Michelle McBean, Rachel Thijssen, Thomas Conway, Mary Ann Anderson, John F Seymour, David A Westerman, Peter E Czabotar, David CS Huang, Andrew W Roberts

Journal article  |  2020  |  Blood